BBy utilizes a proprietary condensing technology to remove unbound water from breast milk, creating a shelf-stable powder that retains its nutritional and immunological properties. This method eliminates the need for freezing, reducing energy costs and streamlining the administration process in neonatal intensive care units (NICUs).

The startup develops data-driven decision optimization software that integrates electronic health record (EHR) data to create evidence-based clinical pathways and manage medical decision documentation. This technology enables healthcare providers to enhance clinical outcomes and improve operational efficiency by streamlining care process models.

I2o Therapeutics develops oral formulations of long-acting GLP-1 receptor agonists and other peptide therapies to treat cardio-renal-metabolic diseases. Their approach aims to provide safer and more effective treatment options for patients with these complex conditions.

KayoThera develops first-in-class oral small molecules that inhibit the retinoid and rexinoid nuclear receptor pathways, which are linked to adverse outcomes in late-stage cancers and cardiometabolic diseases. By blocking the formation of retinoid ligands, KayoThera provides new therapeutic options for managing diabetes, obesity, and cancer.

Mesentech has developed a tissue-selective drug delivery system that utilizes novel chemistry to target pharmaceuticals specifically to musculoskeletal tissue, minimizing exposure to non-target organs. Their first clinical program focuses on delivering prostaglandin to enhance the body's regenerative processes for muscle and bone repair.

Optimeos Life Sciences has developed a novel nanoparticle platform for the intracellular delivery of RNA and DNA therapeutics, enabling the co-encapsulation of multiple active pharmaceutical ingredients while enhancing tissue targeting and reducing immune activation. This technology addresses the limitations of traditional lipid nanoparticle systems, offering a superior dosing profile for more effective disease modification.

The startup has developed a drug discovery and delivery platform that utilizes proprietary nanotechnology to create oral enzyme therapies. This technology protects enzymes with a nano-shield and targets them to the mucus of the small intestine, reducing the need for multiple pills in the treatment of digestive diseases.

Persperion Diagnostics develops advanced diagnostic solutions utilizing accurate touch-based sweat sensing technology. This platform enables non-invasive monitoring and data acquisition for health applications. The company provides a novel method for gathering physiological insights directly through skin contact.

SightStream Biotherapeutics develops cytoprotective agents aimed at reversing ocular cell death caused by various retinal diseases. Their technology targets cellular stress responses to preserve vision and improve outcomes for patients suffering from degenerative eye conditions.